Boulder biopharma miRagen Therapeutics names 2 new execs
BOULDER — MiRagen Therapeutics Inc., a clinical-stage biopharmaceutical company based in Boulder, has appointed Adam Levy as its chief business officer and Chris Morl as chief operating officer, as the company moves into human clinical trials for two of its products.
Morl has been miRagen’s chief business officer since May 2013.
Levy has 16 years of advisory experience primarily in the life sciences sector. He was vice president at Wedbush Securities where he served since 2013 in the health-care investment banking group. He has expertise in corporate strategy, mergers and acquisitions, and partnering with experience in completing more than $30 billion in financing and advisory transactions.
SPONSORED CONTENT
How dispatchable resources enable the clean energy transition
Platte River must prepare for the retirement of 431 megawatts (MW) of dispatchable, coal-fired generation by the end of the decade and address more frequent extreme weather events that can bring dark calms (periods when there is no sun or wind).
MiRagen is using micro-RNA genetic material to develop drugs capable of treating a variety of illnesses.
Bill Marshall, miRagen’s president and chief executive, said the two appointments will enhance the company’s capabilities as it progresses into first-in-human clinical trials for MRG-106 and MRG-201.
MRG-106 is designed to reduce the proliferation of cancer in lymphoma cells, and MRG-201 targets another micro-RNA to treat cardiac, renal, hepatic and pulmonary fibrosis and systemic sclerosis.
For certain cardiovascular disease programs, miRagen has a collaboration and license agreement with Servier, an independent French research-based pharmaceutical company. MiRagen retains all rights for the Servier-partnered programs in the U.S. and Japan.
